Skip to main content

Table 3 Percentage of CD4+25+ T cell Subset

From: Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

Pt. #

Pre(0w)

Post(8w)

R-M-1

12.47%

1.70%

R-G-2

10.00%

1.59%

R-K-3

1.02%

1.88%

R-H-4

4.40%

5.83%

R-N-5

4.74%

6.20%

R-L-6

2.70%

3.59%

B-S-1

3.31%

5.94%

B-H-2

4.54%

9.29%

B-L-3

3.66%

7.05%

B-Y-4

8.18%

6.08%